Valproate metabolism during valproate-associated hepatotoxicity in a surviving adult patient

• Published in: Epilepsy research Vol. 41; no. 3; pp. 259 - 268
• Main Authors: McLaughlin, Daniel B, Eadie, Mervyn J, Parker-Scott, Suzanne L, Addison, Russell S, Henderson, Robert D, Hooper, Wayne D, Dickinson, Ronald G
• Format: Journal Article
• Language: English
• Published: Amsterdam Elsevier B.V 01.10.2000; Elsevier
• Subjects: Adult; Anticonvulsants; Anticonvulsants - adverse effects; Anticonvulsants - pharmacokinetics; Biological and medical sciences; Biotransformation; Chemical and Drug Induced Liver Injury - metabolism; Drug toxicity and drugs side effects treatment; Electroencephalography; Epilepsies, Partial - complications; Epilepsies, Partial - drug therapy; Hepatotoxicity; Humans; Liver Function Tests; Male; Medical sciences; Metabolism; Pharmacology. Drug treatments; Tomography, X-Ray Computed; Toxicity: digestive system; Valproate; Valproic Acid - adverse effects; Valproic Acid - pharmacokinetics; β-Oxidation; Anticonvulsants; Metabolism; Hepatotoxicity; β-Oxidation; Valproate; Human; Nervous system diseases; Toxicity; Epilepsy; Hepatic disease; Anticonvulsant; Valproic acid; Cerebral disorder; Case study; Central nervous system disease; Digestive diseases; Adult
• ISSN: 0920-1211; 1872-6844
• DOI: 10.1016/S0920-1211(00)00151-0

The plasma profiles of valproate (VPA), its β-oxidation metabolites E-2-en-VPA and 3-oxo-VPA and its terminal desaturation metabolite 4-en-VPA, have been measured in a patient receiving NaVPA 1000 mg twice per day from early in the course of serious hepatotoxicity and for 2 weeks after the drug was stopped. Concurrent profiles of liver, renal and haematological function parameters were available. Relative to concurrent plasma VPA concentrations, E-2-en-VPA concentrations were not different to those of the VPA-treated epileptic population at any stage of the illness, whereas 3-oxo-VPA concentrations relative to concurrent VPA concentrations were abnormally high early in the toxicity, abnormally low at its peak (3–5 days later), and comfortably within normal limits for the treated epileptic population late in the recovery phase (9–13 days from the onset). When measurable, plasma 4-en-VPA concentrations were not elevated. The elimination half-life of VPA during the recovery phase was 100 h, which is some 6–12 times greater than values reported for this parameter in normal patients. These data clearly define, in this patient, a link between idiosyncratic VPA-associated hepatotoxicity at its onset and peak and the later stages of VPA β-oxidation. Whether the β-oxidation abnormalities are causative or a consequence of an as yet undefined defect is unknown. In this patient, 4-en-VPA was unlikely to have been involved in the pathogenesis of the toxicity.